Citations 2
Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.
Kumar, Shaji , Vij, Ravi , Pegourié, Brigitte, Benboubker, Lotfi , Gasparetto, Cristina, Diehl, Susan, Alzate, Stefanie, Dunbar, Martin, Zhu, Ming , Maciag, Paulo , Verdugo, Maria E., Kaufman, Jonathan L. , Mıkhael, Joseph , Facon, Thierry T.F. , Gasparetto, Cristina , Amiot, Martine , Moreau, Philippe , Ross, Jeremy A. , Agarwal, Suresh K, Leverson, Joel D. , Touzeau, Cyrille
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8032-8032
Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Chanan‐Khan, Asher , Agarwal, Amit , Kumar, Shaji , Diehl, Susan, Cordero, Jaclyn, Munasinghe, Wijith, Zhu, Ming , Maciag, Paulo , Verdugo, Maria E., Moreau, Philippe , Roberts, Andrew W. , Facon, Thierry T.F. , Touzeau, Cyrille , Ross, Jeremy A. , Salem, Ahmed Hamed , Leverson, Joel D. , Harrison, Simon J
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8011-8011